**Final assessment of the current clinical validation report**

### Strengths (keep these)
- Strict unexposed design (9 pure TEST + 13 CALIB, zero training mutations) is clean and defensible.
- 100 % containment on all 9 pure TEST variants across all three antibiotics is the strongest result.
- Zero false-safety errors (0/729) remains the most important clinical safety property.
- Binary classification metrics on the 612 held-out test positions are reasonable.
- Inclusion of both BLDB hospital strains and Chen wet-lab EC₅₀ mutants improves credibility.

### Critical remaining weaknesses
1. **Almost every clinical call is still “Ambiguous”**  
   The two-sided intervals are so wide that the model almost never issues a decisive Certified Resistant or Certified Susceptible call on the 22 variants. This severely limits claimed decision utility.

2. **Interval widths are still large**  
   AMP ≈ 14.7, CTX ≈ 8.3, MEM ≈ 8.8 log₂ units. High containment under these widths is expected and does not prove high precision.

3. **M154L point-estimate bias is large and unaddressed**  
   Model predicts strongly negative fitness while true values are positive. Containment occurs only because of width.

4. **One clear miss**  
   M248L on Meropenem is not contained.

5. **Missing decisive-call statistics**  
   You still need the counts of Certified Resistant / Certified Susceptible / Ambiguous under both two-sided and (preferably) one-sided rules.

### Bottom line
The report is now rigorous in its data-partitioning and containment claims. However, because virtually all clinical variants remain Ambiguous under the current two-sided intervals, it does **not** yet demonstrate strong actionable clinical decision utility.

**Highest-leverage next step** (still zero retraining):
- Switch the primary clinical guarantee to the **one-sided upper conformal bound**.
- Recompute quantiles only on the original calibration set.
- Re-evaluate the same 22 variants and report the new (much tighter) upper margins + decisive-call counts.

Until that is done, the clinical utility section remains the weakest part of the paper.